Skip to content
Open access · CC-BY via OpenAlex

Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension

Rui Li, Zhile Liu, Wensou Huang, Yongjian Guo, Chan Xie, Hongmei Wu, Jianxin Liu, Xiaoyang Hong, Xiaobin Wang, Jingjun Huang, Mingyue Cai, Zhaoxiong Guo, Licong Liang, Liteng Lin, Kangshun Zhu

Cellular and Molecular Gastroenterology and Hepatology · 2024 · ▲ 15 citations

Abstract

BACKGROUND & AIMS: Cirrhotic portal hypertension (CPH) is the leading cause of mortality in patients with cirrhosis. Over 50% of patients with CPH treated with current clinical pharmacotherapy still present variceal bleeding or sometimes death owing to insufficient reduction in portal pressure. Elevated intrahepatic vascular resistance (IHVR) plays a fundamental role in increasing portal pressure. Because of its potent effect in reducing portal pressure and maintaining normal portal inflow to preserve liver function, lowering the IHVR is acknowledged as an optimal anti-CPH strategy but without clinical drugs. We aimed to investigate the protective effect of microbial-derived Urolithin A (UroA) in IHVR and CPH. METHODS: Carbon tetrachloride or bile duct ligation surgery was administered to mice to induce liver fibrosis and CPH. 16S rRNA gene sequencing was used for microbial analysis. Transcriptomics and metabolomics analyses were employed to study the host and cell responses. RESULTS: UroA was remarkably deficient in patients with CPH and was negatively correlated with disease severity. UroA deficiency was also confirmed in CPH mice and was associated with a reduced abundance of UroA-producing bacterial strain (Lactobacillus murinus, L. murinus). Glutaminolysis of hepatic stellate cells (HSCs) was identified as a previously unrecognized target of UroA. UroA inhibited the activity of glutaminase1 to suppress glutaminolysis, which counteracted fibrogenesis and contraction of HSCs and ameliorated CPH by relieving IHVR. Supplementation with UroA or L. murinus effectively ameliorated CPH in mice. CONCLUSIONS: We for the first time identify the deficiency of gut microbial metabolite UroA as an important cause of CPH. We demonstrate that UroA exerts an excellent anti-CPH effect by suppressing HSC glutaminolysis to lower the IHVR, which highlighted its great potential as a novel therapeutic agent for CPH.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.jcmgh.2024.101379
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
Li, R., Liu, Z., Huang, W., Guo, Y., Xie, C., Wu, H., Liu, J., Hong, X., Wang, X., Huang, J., Cai, M., Guo, Z., Liang, L., Lin, L., &amp; Zhu, K. (2024). Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension. <em>Cellular and Molecular Gastroenterology and Hepatology</em>. https://doi.org/10.1016/j.jcmgh.2024.101379
Vancouver
Li R, Liu Z, Huang W, Guo Y, Xie C, Wu H, et al. Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension. Cellular and Molecular Gastroenterology and Hepatology. 2024. doi:10.1016/j.jcmgh.2024.101379.
BibTeX
@article{rui2024Microb, title = {Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension}, author = {Rui Li and Zhile Liu and Wensou Huang and Yongjian Guo and Chan Xie and Hongmei Wu and Jianxin Liu and Xiaoyang Hong and Xiaobin Wang and Jingjun Huang and Mingyue Cai and Zhaoxiong Guo and Licong Liang and Liteng Lin and Kangshun Zhu}, journal = {Cellular and Molecular Gastroenterology and Hepatology}, year = {2024}, doi = {10.1016/j.jcmgh.2024.101379}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings